Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged 18 years or over~2. Patients have been diagnosed with Rheumatoid Arthritis (RA) for at least 3 months~3. Patient has active RA~4. Patient has taken a stable dose of methotrexate for at least 3 months~Exclusion Criteria:~1. Patient has been previously treated with adalimumab~2. Patient has been previously treated or has ongoing treatment with prohibited medications~3. Patient has been immunised with a live or attenuated vaccine in past 4 weeks~4. Patient has positive result for HIV, HBV, HCV or TB infection~Other Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FKB327 (Type: EXPERIMENTAL): Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
- Humira® (Type: ACTIVE_COMPARATOR): Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).